S-1: Vivos Therapeutics Files for Resale of 1.74 Million Shares Underlying Warrants

Vivos Therapeutics has filed a registration statement for the resale of up to 1,737,259 shares of common stock by a selling stockholder, derived from warrants issued in private placements.

Summary

• Vivos Therapeutics has filed a Form S-1 registration statement with the SEC to allow a selling stockholder to resell up to 1,737,259 shares of the company's common stock.
• These shares are underlying common stock purchase warrants issued to the selling stockholder in private placements in January 2023 and February 2024.
• The warrants include 266,667 shares from the January 2023 warrant and 1,470,592 shares from the Series B-1 and B-2 inducement warrants issued in February 2024.
• Vivos will not receive any proceeds from the resale of these shares, but would receive proceeds if the warrants are exercised for cash.
• If all warrants are exercised for cash, Vivos would receive approximately $8.4 million, which would be used for general corporate purposes and working capital.
• The selling stockholder may sell the shares on the Nasdaq Capital Market, in privately negotiated transactions, or through sales to dealers.
• Vivos' common stock is listed on the Nasdaq under the symbol VVOS, and the last reported sale price on April 4, 2024, was $3.01 per share.
• Vivos is classified as an emerging growth company and is subject to reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The document is primarily factual and related to a stock resale registration. The sentiment is neutral, with potential positives if warrants are exercised, but also risks associated with the company and its stock.

Positives

• If the warrants are exercised for cash, Vivos could receive approximately $8.4 million, which would be used for general corporate purposes and working capital.
• The registration statement allows the selling stockholder to resell shares, potentially increasing liquidity in the market.
• Vivos is an emerging growth company, which allows for reduced reporting requirements, potentially saving on compliance costs.

Negatives

• Vivos will not receive any proceeds from the resale of shares by the selling stockholder unless the warrants are exercised for cash.
• There is no guarantee that the warrants will be exercised, and Vivos may not receive any additional capital.
• The resale of a large number of shares by the selling stockholder could potentially put downward pressure on the stock price.

Risks

• Investing in Vivos' common stock is highly speculative and involves significant risks and uncertainties.
• The company's actual results may differ significantly from future results contemplated in forward-looking statements.
• The company's ability to generate cash flow and profitability and continue as a going concern is uncertain.
• Adverse changes in general market conditions for medical devices and the products and services offered could negatively impact the company.
• The company's ability to adapt to changes in market conditions, including those resulting from the COVID-19 pandemic, rising inflation, and volatile capital markets, could impair operations and financial performance.

Future Outlook

The company intends to use any proceeds received from the exercise of warrants for general corporate purposes and working capital.

Industry Context

Vivos Therapeutics operates in the medical technology industry, specifically focusing on treatments for dentofacial abnormalities and obstructive sleep apnea (OSA). The company is expanding its reach to medical doctors and durable medical equipment (DME) companies, indicating a shift towards a broader, multidisciplinary approach to OSA treatment.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document mentions competitors such as Align Technology (Invisalign) and ResMed (CPAP devices).
• Vivos is attempting to differentiate itself by offering a comprehensive and multidisciplinary approach to OSA treatment, which they call 'The Vivos Method'.
• The company's recent FDA clearances for its CARE appliances to treat severe OSA, along with PAP and/or myofunctional therapy, could give them a competitive advantage.
• The company's focus on the dental industry as a relatively untapped market for OSA treatment is also a differentiating factor.

Stakeholder Impact

• Shareholders may experience fluctuations in the stock price due to the potential resale of a large number of shares.
• The company's ability to execute its business plan and achieve profitability will impact employees and other stakeholders.
• Patients may benefit from the company's continued development and commercialization of innovative treatments for dentofacial abnormalities and OSA.

Next Steps

• The selling stockholder will determine the timing and method for reselling the shares.
• Vivos will continue to execute its business plan, including expanding its network of Vivos-trained dentists and focusing on medical integration.
• The company will monitor the exercise of warrants and utilize any proceeds received for corporate purposes and working capital.

Key Dates

Keywords

Vivos Therapeutics, common stock, warrants, resale, private placement, emerging growth company, VVOS, SEC, registration statement, selling stockholder